Home » Topics » BioWorld Science, Dermatologic

BioWorld Science, Dermatologic
RSS

Preclinical investigation of a small-molecule JAK1/TYK2 inhibitor for psoriasis

Jan. 5, 2015

Warner Chilcott begins phase III study of sarecycline in acne vulgaris

Jan. 5, 2015

Aquinox initiates phase II study of AQX-1125 for atopic dermatitis

Jan. 2, 2015

Cosentyx approved in Japan for psoriasis and psoriatic arthritis

Dec. 30, 2014

FDA approves Soolantra for the once-daily treatment of inflammatory lesions in rosacea

Dec. 24, 2014

European marketing approval granted to Clinuvel's Scenesse

Dec. 23, 2014

Phase I study initiated for ProMetic IV plasminogen

Dec. 22, 2014

RXi Pharmaceuticals updates on phase II program of RXI-109 in scar recurrence prevention

Dec. 22, 2014

Velocity Pharmaceutical and Tigercat Pharma report phase II results for VPD-737

Dec. 18, 2014

Pfizer initiates phase I trial of PF-06700841 in healthy adults and adults with plaque psoriasis

Dec. 17, 2014

Popular Stories

News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Chinese biotechs gain leverage as partners in dealmaking
BioWorld
China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...
Bio Korea 2026 kicks off with spotlight on oligonucleotides
BioWorld
Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
AA meeting of minds as PTC, Novartis push votoplam in HD
BioWorld
What PTC Therapeutics Inc.’s latest data with votoplam might mean in the Huntington’s disease (HD) landscape became grist for Wall Street after the firm unveiled...
University of Western Australia patents 5-HT2A/B modulators
BioWorld Science
University of Western Australia has identified new lysergic acid diethylamide (LSD) analogues acting as 5-HT2A and 5-HT2B modulators reported to be useful for the...